KemPharm Inc
Company Overview
KemPharm, Inc. is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT® (Ligand Activated Therapy) technology platform. The company primarily develops treatments for central nervous system (CNS) conditions and rare diseases. Their main products are designed to improve on the therapeutic and safety profiles of FDA-approved drugs.
The company's lead product candidates include AZSTARYS® for ADHD and KP1077 for Idiopathic Hypersomnia (IH) and Narcolepsy. KemPharm generates revenue through royalties, licensing agreements, and milestone payments from its commercialized products.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $3.69m | $32.26m | - | $1.26m | 0.00% | 3.91% |
| June 30, 2024 | $4.45m | $30.08m | - | $1.84m | 0.00% | 6.12% |
| March 31, 2024 | $3.42m | $23.72m | - | $-194000.0 | 0.00% | 0.82% |
Company Impact
Help us evaluate KemPharm Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.